This document details key terms and definitions used by the Breast Cancer Surveillance Consortium (BCSC).

Contents
BCSC DEFINITIONS FOR BREAST IMAGING EXAMS ................................................................. 2
Screening mammography ........................................................................................................... 2
Screening MRI ............................................................................................................................. 3
Screening/surveillance mammography/MRI with history of breast cancer ............................... 3
Diagnostic mammography ........................................................................................................ 4
Overall assessment ................................................................................................................... 4
Initial assessment (before any work-up) .................................................................................... 5
End-of-day assessment (after same-day work-up) ................................................................. 5
Final assessment (after all work-up) ........................................................................................ 5
Positive and negative result ..................................................................................................... 6
BCSC DEFINITIONS FOR BREAST CANCER DIAGNOSES .................................................... 7
Breast cancer cases .................................................................................................................. 7
Follow-up period for breast cancer diagnosis after a breast imaging exam, for performance 7
Mode of detection for breast cancer cases ............................................................................. 8
PERFORMANCE MEASURES ................................................................................................. 9
REFERENCES ......................................................................................................................... 11
APPENDICES ......................................................................................................................... 12
BCSC DEFINITIONS FOR BREAST IMAGING EXAMS

Screening mammography

Mammograms, including digital breast tomosynthesis, are performed for either screening or diagnostic purposes. To determine whether a mammogram was for screening, different criteria may be applied depending on the population of interest. The following conditions may be used to define a screening mammogram. **Conditions 1-8** comprise the standard strict definition of a screening mammogram in women without a history of breast cancer (BCSC variable `scrmam_c`) often used in BCSC papers.

At a minimum, the exam **must** meet the following conditions:

- **Condition #1: The examination is a mammogram with an indication of “screening”**
  The indication is usually provided by the radiologist or technologist.
- **Condition #2: First mammogram of the day**
  Because multiple exams may occur on the same day, we typically only include only the first exam in the sequence.

One or more of the following conditions may also be applied, to eliminate possible non-screening exams:

- **Condition #3: Unilateral views were not taken**
  Unilateral exams may indicate that the woman had a previous unilateral mastectomy or that the exam was done for diagnostic purposes.
- **Condition #4: No mammogram in prior 9 months**
  A mammogram within the prior nine months may indicate a diagnostic exam since screening exams are not typically done at intervals less than 9 months.

The following four conditions may also be used to select screening mammograms among a population of women without a history of breast cancer.

- **Condition #5: No history of breast cancer**
  History of breast cancer is based on the database or self-report.
- **Condition #6: No history of mastectomy**
  Prior mastectomy is based on the database or self-report and may indicate a prior breast cancer diagnosis.
- **Condition #7: No breast augmentation**
  Breast augmentation is based on self-report and exams usually include diagnostic views.
- **Condition #8: Exam assessment is not BI-RADS® 6**
  BI-RADS 6 (known biopsy-proven malignancy) indicates prior breast cancer. 1

The definition of a screening mammogram may vary depending on the analysis. For example, an analysis may require no self-reported breast symptoms. The analyst can exclude women with symptoms by using the BCSC computed variable `symp_c` (ordered by level of concern: lump, nipple discharge, other symptom not including pain, pain, other symptom not specified, and none). Studies focused on screening/surveillance in women with a personal history of breast
cancer may apply other conditions, defined on page X below. When an analysis includes both screening and diagnostic mammograms, the researchers may prefer to use only the radiologist’s indication for exam to classify the mammogram as screening or diagnostic.

Appendix 1 provides BCSC variable names and SAS code pertaining to the definition of a screening mammograms.

Screening MRI

The BCSC collects up to three indications for magnetic resonance imaging (MRI) exams. The computed variable for indication applies a hierarchy (see Appendix 2) that keeps a screening indication only if no other indication is given.

The following conditions define a screening MRI (variable scrmri_c):

- Condition #1: The examination is an MRI with an indication of “screening”
- Condition #2: First MRI of the day
- Condition #3: Bilateral views taken
- Condition #4: No MRI in prior 9 months
- Condition #5: No history of breast cancer
- Condition #6: No history of mastectomy
- Condition #7: Exam assessment is not BI-RADS 6

Screening/surveillance mammography/MRI with history of breast cancer

Women with a personal history of breast cancer (PHBC) are recommended to have breast imaging exams for screening, also referred to as surveillance exams. These can be identified by the variable scrmambc_c for surveillance mammography and the variable scrmribc_c for surveillance MRI. The BCSC definition of a surveillance exam differs in a few respects from the screening definition in women without PHBC, as summarized in this table:

<table>
<thead>
<tr>
<th></th>
<th>Screening mammography/MRI without PHBC</th>
<th>Screening mammography/MRI with PHBC (surveillance)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of exam</td>
<td>No breast cancer history</td>
<td>≥6 months after breast cancer diagnosis, to allow the initial work-up and treatment period to end</td>
</tr>
<tr>
<td>Indication for exam</td>
<td>Screening</td>
<td>Screening; this is conservative as some screening exams are coded as diagnostic in the first few years after diagnosis</td>
</tr>
<tr>
<td>No prior imaging (of same exam type) time window</td>
<td>9 months</td>
<td>60 days, to allow for shorter screening intervals</td>
</tr>
<tr>
<td>BI-RADS assessment</td>
<td>Exclude BI-RADS 6</td>
<td>Exclude BI-RADS 6</td>
</tr>
<tr>
<td>Other</td>
<td>Not a unilateral exam</td>
<td>No prior bilateral mastectomy (self-report at that exam or prior report in pathology, regardless of laterality)</td>
</tr>
<tr>
<td></td>
<td>No prior mastectomy (self-report at that exam or prior report in pathology, regardless of laterality)</td>
<td></td>
</tr>
</tbody>
</table>

3
Appendix 1 provides BCSC variable names and SAS code pertaining to definitions of a screening mammogram and screening MRI in women with and without a history of breast cancer.

**Diagnostic mammography**

The computed variable `dxmam_c` indicates whether a diagnostic mammogram, including digital breast tomosynthesis, was performed. A diagnostic mammogram is defined as a mammogram with an indication of additional evaluation of recent mammogram, short-interval follow-up, or evaluation of a breast problem or concern (variable `indicate` = 2, 3, or 4). Sometimes multiple diagnostic mammograms may be performed to fully work-up a finding or concern; therefore, only the first diagnostic mammogram performed within 90 days is included in analyses to avoid double counting of exams performed for the same work-up.

Note that performance characteristics differ among the different indications for diagnostic mammogram.\(^2\)\(^-\)\(^5\) We do not recommend combining performance results across the different diagnostic indications.

**Overall assessment**

The BCSC currently uses the classification systems described in the BI-RADS Atlas Fifth Edition (2013) from the American College of Radiology for both mammography and MRI.\(^1\)

**Assessment categories in the BI-RADS manual:**

- 0 indicates that additional imaging evaluation is needed (i.e., incomplete assessment)
- 1-5 indicate the level of suspicion for malignancy
  - 1: negative
  - 2: benign finding
  - 3: probably benign finding
  - 4: suspicious abnormality
  - 5: highly suggestive of malignancy
- 6 indicates a known biopsy-proven malignancy

Each exam contains fields for the left assessment, right assessment, and overall assessment, though not all facilities submit breast-level assessments. The overall assessment (`assmtot_c`) reflects the most serious assessment between the left and right breast. The "highest" assessment between the left and right breast follows a hierarchy ordered from high to low association with cancer risk: 5 > 4 > 0 > 3 > 2 > 1. A BI-RADS 6 assessment should not appear in analyses of screening exams (and thus, should be excluded).

The BCSC computes the overall assessment from the left and right assessments. If left and right assessments are missing, we use the existing overall assessment.
**Initial assessment (before any work-up)**

The overall assessment may include results from additional work-up, which should not be included in most measures of screening performance. Instead, the initial assessment ($assminit_c$), which is made before any additional imaging is performed, should be used. Additional imaging includes diagnostic views or ultrasound done on the same day or used to help make the assessment (BCSC SCC detail: II.18 $diagview = 1-5$, II.20 $useaddv = 1$, II.21 $ultrasnd = 1-5$, II.22 $useultra = 1$, or a second diagnostic imaging exam.)

If additional imaging was done, the initial assessment is set to BI-RADS 0 (needs additional imaging evaluation). Otherwise, the overall assessment is considered to be the first recorded assessment in the imaging series.

We do not code initial assessment for diagnostic mammograms because performance is based on the final assessment.

**End-of-day assessment (after same-day work-up)**

The end-of-day assessment is the BI-RADS assessment at the end of the day and includes any same-day imaging work-up ($assminit_eod_c$). The end-of-day assessment should be used for most performance measures of surveillance mammography, because diagnostic views are often done as part of a surveillance exam and the SCC cannot distinguish these from exams performed to work-up of a new finding. The initial assessment and end-of-day assessment are the same for MRI because same-day additional work-up is not typically done.

**Final assessment (after all work-up)**

The final assessment ($assmfnl_c$) is made after all work-up is completed. Exams with a BI-RADS 0 initial assessment or missing assessment with another exam on the same day are resolved for final assessment. For all other exams, the final assessment is taken to be the overall assessment ($assmtot_c$). The BCSC methods for resolving BI-RADS 0 has been refined over time.

This follow-up algorithm for final assessment was implemented in 2016 (0315b data):

<table>
<thead>
<tr>
<th>Follow-up algorithm for final assessment (applies to mammography and MRI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolve if initial assessment is BI-RADS 0 or missing assessment with another exam on the same day</td>
</tr>
<tr>
<td>Look at all breast imaging exams occurring up to the earliest of 90 days, first biopsy, or breast cancer diagnosis (see note 1 below)</td>
</tr>
<tr>
<td>Use first non-zero BI-RADS from Radiology file or non-missing normal/abnormal result from the Imaging Follow-up file. (BCSC detail: if Imaging Follow-up file used, BI-RADS assessment will be missing but result can be coded)</td>
</tr>
<tr>
<td>Use BI-RADS based on recommendation from last follow-up exam:</td>
</tr>
<tr>
<td>BI-RADS 4, if biopsy recommendation</td>
</tr>
<tr>
<td>BI-RADS 3, if short-interval follow-up</td>
</tr>
<tr>
<td>BI-RADS 2, if normal interval follow-up</td>
</tr>
<tr>
<td>If biopsy done, code as BI-RADS 4</td>
</tr>
</tbody>
</table>
Use BI-RADS based on recommendation from original exam:
- BI-RADS 4, if biopsy recommendation
- BI-RADS 3, if short-interval follow-up
- BI-RADS 2, if normal interval follow-up

If none of the above: Final assessment = missing

Please note:

1. Some cancer registries define the diagnosis date as the date of first evidence of breast cancer. If an abnormality is noted on a screening mammogram and the radiologist gives an assessment of 0, the mammogram date may be used as the diagnosis date even if additional imaging is performed on a later day. Therefore, we may be truncating the follow-up period for final assessment too soon.

2. If the exam used for the final assessment is from the Imaging Follow-up file, the BI-RADS assessment is missing but the mammogram result may still be classified as positive or negative based on the imaging result (imgrslt) or recommendation (imgrec).

3. The definition of final assessment may be modified depending on the analysis. Also, analyses performed in 2015 and before may have used a modified definition based on earlier decisions. Please see the prior version of the BCSC Glossary of Terms.

Positive and negative result

We use the BI-RADS assessment to define an exam result as positive or negative.

For the initial result (resinit_c) and end-of-day result (resinit_eod_c), BI-RADS assessments 1 and 2 are considered negative and 0, 3, 4, and 5 are positive. BCSC began to consider assessments of 3 as positive starting in 2014 to be consistent with changes in the BI-RADS 5th edition. In earlier BCSC studies, BI-RADS 3 was considered positive only if immediate additional imaging (instead of short interval follow-up) was recommended. Please see the prior version of the BCSC Glossary of Terms. According to BI-RADS guidelines, the initial result is used with screening exams for these performance measures: sensitivity, specificity, false-positive recall rate, false-negative recall rate, recall rate, cancer detection rate, and PPV1 (see PERFORMANCE MEASURES). The end-of-day result is used for all screening MRI and screening surveillance mammography.

For the final result (resfnl_c), BI-RADS assessments 1, 2, and 3 are negative; 4 and 5 are positive. Typically, unresolved BI-RADS 0s are excluded; however, one should consider a sensitivity analysis that treats zeros as (a) all positive and (b) all negative, to ensure that exclusion does not bias the results. (Some women with an unresolved BI-RADS 0 exam may have had a biopsy that was not captured by BCSC. Excluding these exams may underestimate the percentage with a biopsy or biopsy recommendation.) According to the BI-RADS guidelines, the final result is used with screening exams for these performance measures: false-positive biopsy recommendation rate, PPV2, and PPV3 (see PERFORMANCE MEASURES) and for all performance measures with diagnostic mammograms. Note that PPV1 is not defined for diagnostic mammograms; in that case, it is the same as PPV2.
BCSC DEFINITIONS FOR BREAST CANCER DIAGNOSES

Breast cancer cases
We usually define breast cancer as invasive carcinoma or ductal carcinoma in situ (DCIS). Some analyses restrict to invasive breast cancer. Lobular carcinoma in situ (LCIS), lymphoma, and sarcoma (including cystosarcoma phyllodes) are excluded from the BCSC definition of breast cancer.

For a woman’s first breast cancer diagnosis, we identify the earliest diagnosis of invasive breast cancer or DCIS using the cancer registry and pathology files and for one site, the biopsy follow-up file. If a woman has diagnoses of both invasive cancer and DCIS separated by more than 60 days, we take the earliest result as her first breast cancer. If the invasive cancer and DCIS diagnoses are within 60 days of each other, we use the invasive result, but retain the earlier date as the diagnosis date. For cancer characteristics (e.g., size, stage, nodal status) we use the most severe result from cancer registry records with the same cancer type (invasive or DCIS) within 60 days of diagnosis. We fill in missing values using the most several result from pathology, or, for one site, biopsy follow-up.

Follow-up period for breast cancer diagnosis after a breast imaging exam, for performance
For calculating performance measures, screening mammograms are followed for one year (365 days) unless the next screening mammogram occurs within 270-365 days, in which case the follow-up period is truncated at that next screening mammogram (Acad Radiol, 2000). Non-screening exams done <270 days after the initial mammogram do not truncate the follow-up period. This definition differs from the American College of Radiology (ACR) BI-RADS definition, which uses a strict 365-day follow-up period. Cancer diagnosed within the follow-up period is indicated by the variable cancscrfu1yr_c with truncation and the variable cancfu1yr_c without truncation.

Screening MRI exams are followed for one year for cancer diagnosis. Truncation at the next screening exam if less than one year does not apply. Cancer diagnosed within the follow-up period is indicated by the variable cancfu1yr_c.

For diagnostic mammograms, the follow-up period for cancer diagnosis is from 30 days before to one year after the exam. Cancer diagnosed within the follow-up period before the exam is indicated by cancdfsufu1yr_c. We include a short period before the diagnostic exam because diagnosis dates assigned by cancer registries often reflect the first evidence of cancer, which can occur on a clinical exam before the diagnostic exam. If multiple cancer diagnoses exist during follow-up then one is chosen using this hierarchy:

1) If one or more cancers are diagnosed within 0-60 days after the exam, then the cancer closest to the exam is chosen.
2) Otherwise, if one or more cancers are diagnosed within 1-30 days before the exam, then the cancer closest to the exam is chosen.
3) Otherwise, if one or more cancers are diagnosed within 61-365 days after the exam, then the cancer closest to the exam is chosen.
Mode of detection for breast cancer cases

The BCSC computed variable for mode of detection (mode_of_detection) is recommended for studies conducted among breast cancer cases. Mode of detection is computed for a woman’s first breast cancer diagnosis.

The following figure illustrates the decision flow and definitions for mode_of_detection, coded as:

1   Screen Detected
2 & 4  Interval Detected (diagnosed within screening interval)
3   Clinically Detected, Not Interval
5   Clinically Detected, Unknown if Interval cancer
Otherwise  Unknown Mode

Figure. Decision Tree for Classifying Mode of Detection (mode_of_detection)

*Breast imaging exam: mammogram, breast ultrasound, or breast MRI
**Screening: indication is routine screen (1) and (>9 months since last screen or time since last breast exam missing)
***Diagnostic: indication is diagnostic (2, 3, or 4)
****Screen detected cancers to be further divided by screening interval for CISNET, keeping information about symptoms. CISNET mode of detection allows prior mammogram up to 42 (rather than 27) months for interval detection.
N.B.: Up to 4000 cases with missing BCSC mode-of-detection are supplemented with mode-of-detection computed from Medicare data
PERFORMANCE MEASURES

Definitions for performance measures often used in BCSC papers are provided in this section.

Positive and negative imaging results

<table>
<thead>
<tr>
<th>Exam Type</th>
<th>Imaging Result</th>
<th>Cancer diagnosis within follow-up period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>SCREENING</td>
<td>Positive (BI-RADS 0, 3, 4, 5)</td>
<td>TP</td>
</tr>
<tr>
<td></td>
<td>Negative (BI-RADS 1, 2)</td>
<td>FN</td>
</tr>
<tr>
<td>DIAGNOSTIC</td>
<td>Positive (BI-RADS 4, 5)</td>
<td>TP</td>
</tr>
<tr>
<td></td>
<td>Negative (BI-RADS 1, 2, 3)</td>
<td>FN</td>
</tr>
</tbody>
</table>

Table adapted from 5th Edition BI-RADS Manual, Follow Up and Outcome Monitoring Section, Fig. 1, page 20.

TP = true positive: a positive exam with DCIS or invasive breast cancer diagnosed within the follow-up period.

FP = false positive: a positive exam with no breast cancer diagnosed within the follow-up period.

TN = true negative: a negative exam with no breast cancer diagnosed within the follow-up period.

FN = false negative: a negative exam with DCIS or invasive breast cancer diagnosed within the follow-up period.

Definitions from BI-RADS 5th Edition: Follow Up and Outcome Monitoring

Sensitivity = TP / (TP + FN)

Sensitivity is the proportion of cancers diagnosed during follow-up that had a positive mammography result.

Specificity = TN / (FP + TN)

Specificity is the proportion of non-cancers during follow-up that had a negative mammography result.

Abnormal interpretation rate = All positive exams / All exams. See note 1 below.

Positive Predictive Value (PPV) has three definitions:

PPV₁ (abnormal finding at screening) = TP / (TP + FP₁), where FP₁ = No known tissue diagnosis within 1 year after positive screening exam (initial assessment of 0, 3, 4, 5).

PPV₁ is the proportion of exams with a positive initial assessment that had a cancer diagnosis during follow-up. PPV₁ should be computed using the initial assessment. If no other PPV definitions are used, PPV₁ may be referred to as PPV. The 5th edition of BI-RADS does not include PPV₁, but we have chosen to include it as a performance measure since PPV₁ was included in earlier BI-RADS editions.
PPV₂ (biopsy recommended) = TP / (TP + FP₂), where FP₂ = No known tissue diagnosis within 1 year after recommendation for tissue diagnosis (final assessment of 4, 5).

PPV₂ is the proportion of exams with a recommendation for biopsy or surgical consult (i.e., positive final result) that had a cancer diagnosis during follow-up.

PPV₃ (biopsy performed) = TP / (TP + FP₃), where FP₃ = Concordant benign tissue diagnosis (or discordant benign tissue diagnosis and no known tissue diagnosis of cancer) within 1 year after recommendation for tissue diagnosis. See note 3 below.

PPV₃ is the proportion of exams with recommendation for biopsy or surgical consult (i.e., positive final result) and biopsy performed within 1 year of the exam that had a cancer diagnosis during follow-up.

**Negative Predictive Value (NPV)** = TN / (TN + FN)

NPV is the proportion of exams with a negative assessment that did not have a cancer diagnosis during follow-up.

**False Positive Rate (FPR)** = FP / (FP + TN)

FPR is the proportion of non-cancers during follow-up that had a positive mammography assessment. FPR equivalent to 1- Specificity.

**Cancer Detection Rate (CDR)** = 1000 * TP / (TP + FP + FN + TN)

CDR is the proportion of exams with both a positive assessment and a cancer diagnosis during follow-up. It is usually computed per 1000 mammograms:

**Notes**

1. BI-RADS 3 is positive at screening, but negative at diagnostic exam. BI-RADS 3 was not intended to be applied to screening exams.

2. The BCSC does not necessarily capture every biopsy that occurs. Therefore, the denominators for PPV₂ and PPV₃ may differ. For PPV₃, the denominator is the number of biopsies for which there is a record in the pathology file and the numerator is the subset of those biopsies that result in a cancer diagnosis.

**Note about follow-up time**

The length of follow-up can affect screening mammogram classifications. For example:

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Assessment</th>
<th>Classification (BCSC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 1, 2000</td>
<td>Screening mammogram</td>
<td>Negative</td>
<td>True negative</td>
</tr>
<tr>
<td>Nov 1, 2000</td>
<td>Screening mammogram</td>
<td>Positive</td>
<td>True positive</td>
</tr>
<tr>
<td>Nov 1, 2000</td>
<td>Cancer diagnosed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Using the ACR definition, the first mammogram would be classified as false negative because breast cancer was diagnosed within 365 days after a negative exam. According to the BCSC definition, however, the follow-up period ended October 31, 2000 because of the November 1, 2000 screening exam—so the first mammogram would be classified as true negative. This results in increased sensitivity compared to the ACR definition.
REFERENCES


SAS code for screening mammogram without personal history of breast cancer:

* INDICATION IS ROUTINE SCREENING;
if indicate = 1 then scrcrit_c1 = 1 ; else scrcrit_c1 = 0 ;

* INITIAL EXAM OF THE DAY;
if examseq = 1 then scrcrit_c2 = 1 ; else scrcrit_c2 = 0 ;

* SCREENING MAMMOGRAMS WITHIN AGE LIMITS (18+);
if 18 <= age_c <= 887 then scrcrit_c3 = 1 ; else scrcrit_c3 = 0 ;

* BILATERAL OR WOMAN-SPECIFIC ROUTINE VIEWS PERFORMED;
if routview in(4,5) or ( routview in(8,9) ) and mammlat in(4,5) )
then scrcrit_c4 = 1 ; else scrcrit_c4 = 0 ;

* NO SELF-REPORT OF BREAST CANCER;
if bchist in(1,2,3,4,5)
   or '00' < ageatdx <= '06'
   or '10' <= ageatdx <= '99'
   or ( dxdati ^= 2 and . < dxdate < examdate )
   or ( dxdati = 2 and year( dxdate ) <= year( examdate ) )
then scrcrit_c5 = 0 ;
else if ( bchist = 0 or ageatdx = '00' ) and dxdate = .
then scrcrit_c5 = 1 ;
else scrcrit_c5 = 9 ;

* NO PREVIOUS BREAST CANCER IN CANCER FILE;
if ( newdxdti ^= 2 and . < newdxdt < examdate )
   or ( newdxdti = 2 and year( newdxdt ) <= year( examdate ) )
then scrcrit_c6 = 0 ;
else if newdxdt = .
   or ( newdxdti ^= 2 and newdxdt >= examdate )
   or ( newdxdti = 2 and year( newdxdt ) > year( examdate ) )
then scrcrit_c6 = 1 ;
else scrcrit_c6 = 9 ;

(Note: newdxdti indicates imputed date part: 1=day imputed, 2=month and day imputed)

* NO IMAGING IN PRIOR 9 MONTHS IN DATABASE;
if ( prvraddt_c = . or ( examdate - prvraddt_c ) >= 270 )
then scrcrit_c7 = 1 ; else scrcrit_c7 = 0 ;

* NO IMAGING IN PRIOR 9 MONTHS FROM LASTDATE, PREVDATE, COMPDATE;
if ( lastdate_c = . or lastdate_c = examdate or ( examdate - lastdate_c ) >= 270 )
   and ( prevdate_c = . or prevdate_c = examdate or ( examdate - prevdate_c ) >= 270 )
   and ( compdate_c = . or compdate_c = examdate or ( examdate - compdate_c ) >= 270 )
then scrcrit_c8 = 1 ; else scrcrit_c8 = 0 ;

* NO BREAST IMPLANTS;
if brstaugm in(0,8,9) .) then scrcrit_c9 = 1 ; else scrcrit_c9 = 0 ;
* ASSESSMENT SHOULD NOT BE ‘6’ (KNOWN BIOPSY-PROVEN MALIGNANCY) IN EITHER THE LEFT, RIGHT, OR OVERALL ASSESSMENT;
    if not ( assessl = 6 or assessr = 6 or assmtot_c = 6 )
    then scrcrit_c10 = 1 ; else scrcrit_c10 = 0 ;

* NO SELF REPORT OF MASTECTOMY;
    if mastect in(0,8,9,.)) and ^(mastectomy_date<examdate and mastectomy_date^=.)
    then scrcrit_c11 = 1 ; else scrcrit_c11 = 0 ;

(Note: mastectomy_date is the earliest diagnosis date in the cancer file where mastectomy is reported)

* ANY MAMMOGRAM PERFORMED;
    if (mamm_c=1) then scrcrit_c12=1; else scrcrit_c12=0;

*** CV: SCREENING MAMMOGRAM WITHOUT PERSONAL HISTORY OF BREAST CANCER ***;
    if scrcrit_c1 = 1 and scrcrit_c2 = 1 and scrcrit_c3 = 1 and
    scrcrit_c4 = 1 and scrcrit_c5 in(1,9) and scrcrit_c6 in(1,9) and
    scrcrit_c7 = 1 and scrcrit_c8 = 1 and scrcrit_c9 = 1 and
    scrcrit_c10 = 1 and scrcrit_c11 = 1 and scrcrit_c12 = 1
    then scrmam_c = 1 ; else scrmam_c = 0 ;

SAS code for screening mammogram without personal history of breast cancer, not including ‘no breast augmentation’ criteria:

*** remove 'no breast implants' criteria;
    scrmam_c2 = (scrcrit_c1 and scrcrit_c2 and scrcrit_c3 and scrcrit_c4 and
    scrcrit_c5 in(1,9) and scrcrit_c6 in(1,9) and scrcrit_c7 and
    scrcrit_c8 and scrcrit_c10 and scrcrit_c11 and scrcrit_c12);

SAS code for screening MRI without personal history of breast cancer:

*** CV: SCREENING MRI WITHOUT PERSONAL HISTORY OF BREAST CANCER ***;
    if mri in(4,5) and /* bilateral MRI */
    indicate_c = 1 and /* indication is screening */
    advseq = 1 and /* first MRI of the day */
    scrcrit_c3 = 1 and /* age 18 or older */
    scrcrit_c5 in(1,9) and /* no self-report of personal history of breast cancer */
    scrcrit_c6 in(1,9) and /* no previous breast cancer in cancer file */
    (prvmridt_c =. or (infodate-prvmridt_c)\geq270) and /* no MRI in prior 9 months */
    scrcrit_c10 =1 and /* no BI-RADS assessment 6 */
    scrcrit_c11 = 1 /* no self-report of prior mastectomy */

    then scrmri_c = 1; else scrmri_c = 0;

(Note: indicate_c is the computed indication for exam - see Appendix 2)
SAS code for screening mammogram with personal history of breast cancer:

```sas
*** CV: SCREENING MAMMOGRAM WITH PERSONAL HISTORY OF BREAST CANCER ***;
if mamm_c = 1 and /* mammogram */
   scrcrit_c1 = 1 and /* indication is screening */
   scrcrit_c2 = 1 and /* first radiology exam of the day */
   scrcrit_c3 = 1 and /* age 18 or older */
   bchist_c = 1 and /* history of breast cancer */
   (prcancdt2 = . or (infodate-prcancdt2)>180) and /* cancer not in prior 6 months */
   (prvmamdt_c = . or (infodate-prvmamdt_c)>60) and /* no mammogram in prior 60 days */
   scrcrit_c10 =1 and /* no BI-RADS assessment 6 */
   (^(. < mast_bilat_date < infodate) and /* no bilateral mastectomy in cancer file */
   mastect ^=4 /* no self-report of bilateral mastectomy */
then scrmambc_c = 1; else scrmambc_c = 0;
```

(Note: prcancdt2 is the most recent prior cancer date and mast_bilat_date is the earliest diagnosis date in the cancer file where bilateral mastectomy is reported)

SAS code for screening MRI with personal history of breast cancer:

```sas
*** CV: SCREENING MRI WITH PERSONAL HISTORY OF BREAST CANCER ***;
if 1<=mri<=5 and /* MRI */
   indicate_c = 1 and /* indication is screening */
   advseq = 1 and /* first advanced imaging exam of the day */
   scrcrit_c3 = 1 and /* age 18 or older */
   bchist_c = 1 and /* history of breast cancer */
   (prcancdt2 = . or (infodate-prcancdt2)>180) and /* cancer not in prior 6 months */
   (prvmridt_c = . or (infodate-prvmridt_c)>60) and /* no MRI in prior 60 days */
   scrcrit_c10 =1 and /* no BI-RADS assessment 6 */
   (^(. < mast_bilat_date<infodate) and /* no bilateral mastectomy in cancer file */
   mastect ^=4 /* no self-report of bilateral mastectomy */
then scrmribc_c = 1; else scrmribc_c = 0;
```

(Note: indicate_c is the computed indication for exam - see Appendix 2, prcancdt2 is the most recent prior cancer date, and mast_bilat_date is the earliest diagnosis date in the cancer file where bilateral mastectomy is reported)
Appendix 2

Indication for MRI without history of breast cancer: hierarchy used in computed variable
MRI exams can have up to three indications. The computed variable for indication applies a hierarchy that keeps a screening indication only if no other indication is given. The first indication that appears in the list below is used in the computed variable:

<table>
<thead>
<tr>
<th>Indication for exam, raw data (indic1, indic2, indic3)</th>
<th>Raw code</th>
<th>Indication for exam, computed variable (CV) (indicate_c)</th>
<th>CV code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation for extent of disease of recent breast cancer diagnosis</td>
<td>10</td>
<td>Evaluation for extent of disease or Axillary adenopathy (malignant), unknown primary</td>
<td>6</td>
</tr>
<tr>
<td>Response to chemotherapy</td>
<td>21</td>
<td>Other procedures</td>
<td>5</td>
</tr>
<tr>
<td>Axillary adenopathy (malignant), unknown primary</td>
<td>31</td>
<td>Evaluation for extent of disease or Axillary adenopathy (malignant), unknown primary</td>
<td>6</td>
</tr>
<tr>
<td>Additional evaluation of recent imaging</td>
<td>41</td>
<td>Additional evaluation of recent breast imaging exam</td>
<td>2</td>
</tr>
<tr>
<td>Breast problem</td>
<td>30</td>
<td>Evaluation of breast problem (symptomatic)</td>
<td>4</td>
</tr>
<tr>
<td>Recurrence vs. scar</td>
<td>42</td>
<td>Evaluation of breast problem (symptomatic)</td>
<td>4</td>
</tr>
<tr>
<td>Short interval follow-up</td>
<td>32</td>
<td>Short interval follow-up</td>
<td>3</td>
</tr>
<tr>
<td>Diagnostic, not otherwise specified</td>
<td>70</td>
<td>Diagnostic, not otherwise specified</td>
<td>7</td>
</tr>
<tr>
<td>Implant evaluation*</td>
<td>40</td>
<td>Other procedures</td>
<td>5</td>
</tr>
<tr>
<td>Screening</td>
<td>10</td>
<td>Routine screening (asymptomatic)</td>
<td>1</td>
</tr>
<tr>
<td>Other</td>
<td>50</td>
<td>Other procedures</td>
<td>5</td>
</tr>
<tr>
<td>Unknown</td>
<td>99</td>
<td>Unknown</td>
<td>9</td>
</tr>
<tr>
<td>Structural missing</td>
<td>88</td>
<td>Structural missing</td>
<td>8</td>
</tr>
</tbody>
</table>

* MRI exams done on women with implants can be for screening if the exam includes contrast administration. This cannot be determined in BCSC data so implant evaluation is excluded from screening because some non-contrast exams are performed to evaluate for implant rupture and are not for cancer screening or surveillance. Do not exclude if there is only self-report of breast implants.

SAS code for computed indication for exam (CV0315_v2_2016_05_03.sas):

```sas
if advcrec = 0 then indicate_c = indicate;
else if advcrec = 1 then do ;
   if      indic1 = 20 or indic2 = 20 or indic3 = 20 then indicate_c = 6;
   else if indic1 = 21 or indic2 = 21 or indic3 = 21 then indicate_c = 5;
   else if indic1 = 41 or indic2 = 41 or indic3 = 41 then indicate_c = 6;
   else if indic1 = 31 or indic2 = 31 or indic3 = 31 then indicate_c = 2;
   else if indic1 = 30 or indic2 = 30 or indic3 = 30 then indicate_c = 4;
   else if indic1 = 42 or indic2 = 42 or indic3 = 42 then indicate_c = 4;
   else if indic1 = 70 or indic2 = 70 or indic3 = 70 then indicate_c = 7;
   else if indic1 = 40 or indic2 = 40 or indic3 = 40 then indicate_c = 5;
   else if indic1 = 10 or indic2 = 10 or indic3 = 10 then indicate_c = 1;
   else if indic1 = 50 or indic2 = 50 or indic3 = 50 then indicate_c = 5;
   else if indic1 = 99 or indic2 = 99 or indic3 = 99 then indicate_c = 9;
   else if indic1 = 88 or indic2 = 88 or indic3 = 88 then indicate_c = 8;
end;
```